https://corefacilities.iss.it/dw/ 2026-04-13T22:28:02+02:00 https://corefacilities.iss.it/dw/ https://corefacilities.iss.it/dw/lib/tpl/bootstrap3gscf/images/favicon.ico text/html 2025-08-26T18:26:04+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:controlli_qualita The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area Quality and microbiological controls The Quality Control is the part of the GMP related to the sampling and testing procedures that ensure that the necessary and relevant tests have been carried out and that the product is released, for the use for which it is intended, only after its quality has been verified. text/html 2025-08-26T18:25:50+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:prodotti_cellulari The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area Cell Products FaBioCell can produce all types of cellular drugs, such as: Dendritic cells generated by CD14 + monocytes;T lymphocytes;Natural Killer cells;Stem cells; text/html 2025-08-26T18:25:33+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:produzione The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area GMP Production / Cell manipulation / ATMP Working in a “GMP facilities” or “Cell Factory” became mandatory following the issuance of the European directive 2001/20 which established that the production of experimental drugs must comply with the Good Manufacturing Practices, normally indicated with the English acronym GMP (Good Manufacturing Practice). GMPs are the European guidelines whose application is mand… text/html 2025-08-26T18:25:23+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:ricerca The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area Research GENEVAX Project [Loghi] In the context of the POR FESR, Key Enabling Technologies (KETs) calls, the FaBioCell cell factory has recently received a loan from text/html 2025-08-25T12:21:47+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:richiesta The FaBioCell cell factory terminated its operations as of July 2025. text/html 2025-08-24T01:59:19+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:sidebar Start Access regulation to the Service Service requests Brochure Reserved section ---------- Areas Cytometry EPR FaBioCell cell factory GMP Production / Cell manipulation / ATMP The Quality System in pharmaceutical contextQuality and microbiological controlsCell productsClinical trialsResearchStaffService request NMR & MRI Microscopy Proteomics Next Generation Sequencing Scientific Computing ---------- Services and tools in collaboration text/html 2025-08-26T18:25:11+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:sistema_qualita The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area The Quality System in the pharmaceutical context Since its early stages, the development of a drug must adhere to an appropriate Quality System (SQ) aimed at producing text/html 2025-08-26T18:24:58+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:sperimentazioni The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area Clinical Trials Clinical studies in progress Phase I clinical study of adoptive immunotherapy, characterized by the infusion of autologous Natural Killer (NK) cells, after enrichment and expansion, in patients with acute lymphoblastic leukemia (LLA) Philadelphia (Ph)+ in complete haematological remission but with persistent recurrent minimal residual disease (in collaboration with the Policlinico Umberto I, S… text/html 2025-08-26T18:24:45+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:staff The FaBioCell cell factory terminated its operations as of July 2025. FaBioCell Area Staff and contacts Qualified Person Luciano Castiello ☎ +39 06 4990 6080 Quality Assurance Luciano Castiello Production Laura Santodonato, Enrica Montefiore Quality Controls text/html 2025-08-26T18:24:36+02:00 https://corefacilities.iss.it/dw/doku.php?id=en:recycler:20250823-fabiocell:start The FaBioCell cell factory terminated its operations as of July 2025. Area FaBioCell Cell factory General presentation FaBioCell is a “cell factory”, namely a pharmaceutical factory authorized to produce drugs for cell therapies. Cell therapies, together with gene therapy drugs and tissue engineering products, constitute the family of Advanced Therapy Medicinal Products or ATMP.